Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
Phase 3
Recruiting
Conditions
Prostate Cancer
Interventions
Drug: Leuprolide, Degarelix or Relugolix
Radiation: Stereotactic body radiation therapy/radiosurgery (SBRT)
Subscribe
First Posted Date
2024-05-03
Last Posted Date
2024-05-03
Lead Sponsor
NYU Langone Health
Target Recruit Count
392
Registration Number
NCT06397703
Locations
🇺🇸
NYU Langone Health, New York, New York, United States
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy